At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LENZ Therapeutics
Closed 01-14 16:00:00 EST
18.59
+1.99
+11.99%
盘后18.84
+0.25+1.34%
19:53 EST
High18.70Low16.21Vol1.82M
Open16.41D1 Closing16.60Amplitude15.00%
Mkt Cap581.68MTradable Cap291.72MTotal Shares31.29M
T/O32.72MT/O Rate11.57%Tradable Shares15.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Alterity Therapeutics Issues 18 Million Unlisted Options Under Employee Scheme
TIPRANKS  ·  09:33
Alterity Therapeutics Issues 18 Million Unlisted Options Under Employee Scheme
Plus Therapeutics Prices Upsized $15 Million Public Offering
MT Newswires Live  ·  03:49
Plus Therapeutics Prices Upsized $15 Million Public Offering
LENZ Therapeutics: Early VIZZ Launch, Targeted DTC Campaign, and Differentiated Presbyopia Profile Underpin Buy Rating
TIPRANKS  ·  03:16
LENZ Therapeutics: Early VIZZ Launch, Targeted DTC Campaign, and Differentiated Presbyopia Profile Underpin Buy Rating
Beam Therapeutics: De-Risked Late-Stage Pipeline, Clear FDA Pathways, and Strong Cash Runway Underscore Buy Rating and $80 Target
TIPRANKS  ·  01:07
Beam Therapeutics: De-Risked Late-Stage Pipeline, Clear FDA Pathways, and Strong Cash Runway Underscore Buy Rating and $80 Target
Denali Therapeutics Advances New Early-Stage Alzheimer’s Drug Into Phase 1b Testing
TIPRANKS  ·  00:32
Denali Therapeutics Advances New Early-Stage Alzheimer’s Drug Into Phase 1b Testing
Stock Track | LENZ Therapeutics Soars 5.24% Intraday on Launch of "Make It Vizzable" Campaign with Sarah Jessica Parker
Stock Track  ·  00:14
Stock Track | LENZ Therapeutics Soars 5.24% Intraday on Launch of "Make It Vizzable" Campaign with Sarah Jessica Parker
BRIEF-Lenz Therapeutics Launch Of “Make It Vizzable” With Sarah Jessica Parker As A Brand Ambassador
Reuters  ·  01-14 21:37
BRIEF-Lenz Therapeutics Launch Of “Make It Vizzable” With Sarah Jessica Parker As A Brand Ambassador
Lenz Therapeutics: Launch of “Make It Vizzable” With Sarah Jessica Parker as a Brand Ambassador
THOMSON REUTERS  ·  01-14 21:35
Lenz Therapeutics: Launch of “Make It Vizzable” With Sarah Jessica Parker as a Brand Ambassador
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
GlobeNewswire  ·  01-14 21:30
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
Plus Therapeutics prices 39.5M units at 38c in upsized public offering
TIPRANKS  ·  01-14 21:17
Plus Therapeutics prices 39.5M units at 38c in upsized public offering
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
GlobeNewswire  ·  01-14 21:00
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
Travere Therapeutics price target lowered to $43 from $47 at BofA
TIPRANKS  ·  01-14 19:51
Travere Therapeutics price target lowered to $43 from $47 at BofA
Buy Rating Reaffirmed on Travere Therapeutics: Attractive Risk/Reward Despite FDA Delay and Near‑Term Catalyst Reset
TIPRANKS  ·  01-14 18:36
Buy Rating Reaffirmed on Travere Therapeutics: Attractive Risk/Reward Despite FDA Delay and Near‑Term Catalyst Reset
Will Dispatch Bio CAR T Solid Tumor Trial Shift CARsgen Therapeutics' (SEHK:2171) Narrative?
Simply Wall St.  ·  01-14 18:25
Will Dispatch Bio CAR T Solid Tumor Trial Shift CARsgen Therapeutics' (SEHK:2171) Narrative?
Dianthus Therapeutics: Clinical Momentum, Pipeline Expansion, and Undervalued Catalysts Support Buy Rating
TIPRANKS  ·  01-14 17:36
Dianthus Therapeutics: Clinical Momentum, Pipeline Expansion, and Undervalued Catalysts Support Buy Rating
Chordia Therapeutics Narrows Quarterly Loss but Forecasts Continued Full-Year Red Ink
TIPRANKS  ·  01-14 14:57
Chordia Therapeutics Narrows Quarterly Loss but Forecasts Continued Full-Year Red Ink
TFI Asset Management Reaffirms Their Buy Rating on CARsgen Therapeutics Holdings Ltd. (2171)
TIPRANKS  ·  01-14 13:05
TFI Asset Management Reaffirms Their Buy Rating on CARsgen Therapeutics Holdings Ltd. (2171)
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  01-14 05:05
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics announces FDA extends review of FILSPARI sNDA
TIPRANKS  ·  01-14 02:35
Travere Therapeutics announces FDA extends review of FILSPARI sNDA
Dogwood Therapeutics Raises Capital via Registered Direct Financing
TIPRANKS  ·  01-14 01:57
Dogwood Therapeutics Raises Capital via Registered Direct Financing

Introduction

Company Name.
Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Issue price:
--